Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19
By Yang Yang, C. Shen, Jinxiu Li, Jing Yuan, Jinli Wei, Fengming Huang, Fuxiang Wang, Guobao Li, Yanjie Li, L. Xing and 15 more. Journal of Allergy and Clinical Immunology, 2020
624 citations recorded by the source corpus.
Background The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 was first reported in Wuhan, December 2019, and continuously poses a serious threat to public health, highlighting the urgent need of identifying biomarkers for disease severity and progression. Objective We sought to identify biomarkers for disease severity and progression of COVID-19. Methods Forty-eight cytokines in the plasma samples from 50 COVID-19 cases including 11 critically ill, 25 severe, and 14 moderate patients were measured and analyzed in combination with clinical data. Results Levels of 14 cytokines were found to be significantly elevated in COVID-19 cases and showed different expression profiles in patients with different disease severity. Moreover, expression levels of IFN-γ–induced protein 10, monocyte chemotactic protein-3, hepatocyte growth factor, monokine-induced gamma IFN, and macrophage inflammatory protein 1 alpha, which were shown to be highly associated with disease severity during disease progression, were remarkably higher in critically ill patients, followed by severe and then the moderate patients. Serial detection of the 5 cytokines in 16 cases showed that continuously high levels were associated with deteriorated progression of disease and fatal outcome. Furthermore, IFN-γ–induced protein 10 and monocyte chemotactic protein-3 were excellent predictors for the progression of COVID-19, and the combination of the 2 cytokines showed the biggest area under the curve of the receiver-operating characteristics calculations with a value of 0.99. Conclusions In this study, we report biomarkers that are highly associated with disease severity and progression of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of severe acute respiratory syndrome coronavirus 2 infection, and provide potential therapeutic targets and strategies.
Subfields: Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/851046bb0001f2b6f7915e72f13cdb180237ea3f
Citations in the corpus
- Predictors of COVID-19 severity: A literature review (2020, neutral): “at least 14 cytokines have been shown to be increased in critically ill patients.(115)”
- Aging in COVID-19: Vulnerability, immunity and intervention (2020, neutral): “Th17 activation is also believed to play a role in contributing to cytokine storm in severe COVID-19, suppression of which is proposed to be a mechanism underlying anti-IL-6R therapy (Lagunas-Rangel and Chavez-Valencia, 2020) and other immunotherapies (Wu and Yang, 2020).”
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity (2020, neutral): “CXCL10 (IP-10), IL-8, and IL-6 were elevated in acute COVID19 (p < 0.0001, p < 0.05, p < 0.001; Figures S5A–S5C) and correlated with disease severity (Figure 5A), consistent with large cohort studies of plasma cytokines (Chen et al., 2020; Laing et al., 2020; Mathew et al., 2020; Yang et al., 2020).”